Novel Engineering of Immune Cells Holds Promise for Mesothelioma Patients
Research & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
Testimonials
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
APA
Povtak, T. (2020, October 16). Novel Engineering of Immune Cells Holds Promise for Mesothelioma Patients. Asbestos.com. Retrieved January 31, 2023, from https://www.asbestos.com/news/2014/01/03/immunotherapy-clinical-trial/
MLA
Povtak, Tim. "Novel Engineering of Immune Cells Holds Promise for Mesothelioma Patients." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2014/01/03/immunotherapy-clinical-trial/.
Chicago
Povtak, Tim. "Novel Engineering of Immune Cells Holds Promise for Mesothelioma Patients." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2014/01/03/immunotherapy-clinical-trial/.
Patients with advanced malignant pleural mesothelioma and metastatic pancreatic cancer received surprisingly positive results during a small, recent Phase I clinical trial involving a novel engineering of immune cells.
The trial was done at the Abramson Cancer Center in Philadelphia, and the results were published in Cancer Immunology Research.
It accentuated the growing belief that the next big step in combating mesothelioma will come from immunotherapy, which uses a patient’s own immune system to fight deadly diseases.
“These results, albeit preliminary, are very promising,” said Carl H. June, M.D., professor of pathology and laboratory medicine at the University of Pennsylvania and director of translational research at Abramson.
The trial involved elderly patients with advanced cancers that had not responded to prior treatments.
Using a Patient’s Own Immune System
Researchers harvested a patient’s own immune cells, then clinically engineering them with a molecule that attaches to a mesothelin protein that is common in cancer cells. It helps the immune cells to recognize and destroy the cancer cells more effectively.
The engineered cells are known as chimeric antigen receptor T cells (CARTmeso cells) and considered a form of personalized therapy currently conducted at leading research laboratories.
These types of CART cells previously have shown promising results in some types of leukemia and lymphoma, but have not been successful with solid tumors in the past because of off-target toxicity that causes serious problems for surrounding healthy cells.
The latest trial involved a different modification that allows the T cells to express the chimeric antigen receptor (CAR) for just three days, instead of the permanent transformation that causes much of the off-target problem.
Strategy Eliminates the Toxicity
The new method allows the T cells to revert to what they were before the modification. The new strategy involves multiple infusions of the CARTmeso cells, which would allow doctors to quickly change course with therapy, and eliminates much of the toxicity.
The mesothelioma patient in the study, whose condition had been worsening, received three infusions of the CARTmeso cells, and his disease stabilized. The patient with pancreatic cancer received eight infusions of CARTmeso cells, and he showed a 40 percent decrease in tumor cells.
“We found that the temporary CARs we engineered were safe, with no significant off-target, off-tumor toxicity,” June told Science Codex. “We have evidence of antitumor effects in two patients whose advanced tumors failed previous therapies.”
The trial originally was designed to evaluate the safety of the CARTmeso cells, the novel engineering process, and the manufacturing feasibility. The researchers, after harvesting the immune cells, reproduced them in large numbers, which allowed the multiple infusions. The engineered cells were reintroduced to the patient’s body.
“We found that these CARTmeso cells not only have antitumor activity, but they also act like a vaccine, and trigger a response against the patient’s own tumor,” June said. “This new form of CAR therapy provides a new tool to evaluate therapies for solid cancers.”
